Scotiabank to acquire MD Financial in $2.6bn deal

By zaymalz malz
Share

Scotibank has announced that it has signed an agreement with the Canadian Medical Association (CMA) to acquire leading medical-centric financial services company MD Financial Management in a deal worth CAD$2.585bn.

MD Financial holds approximately $49bn in assets under management, serving a significant number of doctors and physicians across Canada.

See also:

“MD has served the distinct financial needs of Canada's physician community for decades and has delivered strong results,” said Brian Porter, President and CEO at Scotiabank.

“Through this transaction, MD clients will benefit from a greatly expanded range of financial solutions, including access to expertise across our wealth and asset management businesses.”

The transaction will see Scotiabank acquiring 19.7mn shares at a price of $76.15 per share.

At the close of the acquisition Scotibank and CMA will enter into a 10-year partnership that will see CMA promoting Scotiabank as the preferred provider of financial products and services to physicians across Canada.

“With its existing capabilities in investment management and digital banking, its track record of philanthropy, and its team-based approach to wealth management that addresses the entirety of a client's life, Scotiabank is the best possible partner to help continue MD's proud history of meeting the specific needs of Canada's physicians and their families,” said Brian Peters, MD Financial’s President and CEO.

The deal is expected to complete in Q4 2018.

Share

Featured Articles

UK Entrepreneurs Ratchet Up Selling Off Their Businesses

British business owners spooked by impending tax hikes accelerate plans to sell off their businesses, as executives of UK-listed companies dump shares

UK Employment Rights Bill - What It Means for Your Business

Government introduces the biggest reform to UK employment law in a generation. Here’s what it means for your business

Q&A: Former Novartis CEO Daniel Vasella - McKinsey

Former Novartis CEO Daniel Vasella talks to McKinsey about how his attitudes to leadership have changed and why he’s not afraid to be vulnerable

Share of Population Who are Millionaires to Drop by 20%

Corporate Finance

Why Are US CEOs Stampeding for the Exit Sign?

Human Capital

Companies Wasting Millions on AI Spending - MIT Professor

Technology & AI